Physician profile
Stuart E Shulruff
NPI 1871590448
$3,502.80
in general payments reported to CMS, 2019-2025
34 companies · $599 in 2025
The $599 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $112 · 2021: $262 · 2022: $438 · 2023: $613 · 2024: $917 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,129.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $524.87 | 2019-2025 | |
| Amgen INC. | $374.41 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $277.27 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $229.46 | 2019-2024 | Xarelto |
| Abbott Laboratories | $216.39 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Pfizer INC. | $211.19 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.24 | 2019-2021 | |
| Irhythm Technologies, INC. | $127.08 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.08 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $116.76 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $91.45 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $83.95 | 2019-2024 | |
| Boston Scientific Corporation | $80.74 | 2019-2024 | Watchman Flx |
| Impulse Dynamics (USA) INC. | $73.45 | 2023-2024 | Optimizer, Optimizer |
| Atricure, INC. | $73.35 | 2023-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $72.97 | 2019-2025 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $72.13 | 2019-2023 | Camzyos |
| Amarin Pharma, INC. | $70.06 | 2019-2022 | |
| Heartflow, INC. | $69.05 | 2023-2025 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $58.53 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $50.16 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $48.18 | 2021-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $47.16 | 2024 | Arcalyst |
| Surmodics, INC. | $28.37 | 2022 | |
| Abiomed | $27.78 | 2025 | |
| Philips North America LLC | $26.88 | 2024 | (5044) Mcot |
| Cvrx, INC. | $26.05 | 2024 | Barostim Neo System |
| Arbor Pharmaceuticals, INC. | $24.48 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.22 | 2019-2020 | |
| Recor Medical INC | $19.65 | 2025 | Paradise Ultrasound Renal Denervation System |
| Althera Pharmaceuticals LLC | $17.16 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $15.39 | 2024 | Opsumit |
| Kestra Medical Technology Services, INC. | $14.83 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals, Ltd. | $14.06 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Shulruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.